Oruka Therapeutics, Inc. 10-Q

ITEM 5. OTHER INFORMATION Item 5.08 Shareholder Director Nominations On May 2, 2022, the Company determined that it anticipates that the date of its 2022 annual stockholder meeting will be more than 30 calendar days after the date of the Company’s 2021 annual stockholder meeting, but has not made a final determination as to such date. Once available, the Company will file an amendment to this report or file a Current Report on Form 8-K to (i) announce the date of the Company’s 2022 annual stockholder meeting; and (ii) to disclose the date by which a nominating stockholder or nominating stockholder group must submit a notice on Schedule 14N, which date shall be a reasonable time before the Company mails its proxy materials for its 2022 annual stockholder meeting 48 ITEM 6. EXHIBITS EXHIBIT INDEX The following documents are filed as part of this quarterly report on Form 10-Q. The Company will furnish a copy of any exhibit listed to requesting stockholders upon payment of the Company’s reasonable expenses in furnishing those materials. Incorporated by Reference (1) Exhibit No. Description Form Filing Date Number Filed Herewith 3.1 Amended and Restated Certificate of Incorporation of the Registrant, as amended . 10-K 3/27/2009 3.1 3.1(a) Certificate of Amendment to Restated Certificate of Incorporation . 8-K 3/5/2013 5.1 3.1(b) Certificate of Amendment to Restated Certificate of Incorporation . 8-K 9/3/2015 3.1 3.1(c) Certificate of Amendment to Restated Certificate of Incorporation . 8-K 4/3/2019 3.1 3.2 Amended and Restated Bylaws of the Registrant, as amended . 8-K 6/28/2021 3.1 4.1 Reference is made to Exhibits 3.1, 3.1(a), 3.1(b) and 3.2 4.2 Form of Common Stock Certificate . 10-Q 5/8/2019 4.2 31.1 Certification of Principal Executive Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 . X 31.2 Certification of Principal Financial Officer pursuant to Rule 13a-14(a) or 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 . X 32.1 Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. sec. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 . X 101.INS Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because XBRL tags are embedded within the Inline XBRL document X 101.SCH Inline XBRL Taxonomy Extension Schema Document (filed electronically herewith) X 101.CAL Inline XBRL Taxonomy Extension Calculation Linkbase Document (filed electronically herewith) X 101.LAB Inline XBRL Taxonomy Extension Label Linkbase Document (filed electronically herewith) X 101.PRE Inline XBRL Taxonomy Extension Presentation Linkbase Document (filed electronically herewith) X 49 Incorporated by Reference (1) Exhibit No. Description Form Filing Date Number Filed Herewith 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document (filed electronically herewith) X 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). (1) The SEC file number for all items incorporated by reference herein from reports on Forms 10-K, 10-Q and 8-K is 000-22873. 50 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ARCA biopharma, Inc. (Registrant) By: /s/ C. Jeffrey Dekker C. Jeffrey Dekker Chief Financial Officer (Principal Financial and Accounting Officer) Dated: May 2, 2022 51